# A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors

> **NCT05258266** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Nanjing Zenshine Pharmaceuticals** · enrollment: 76 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** ZX-101A

## Key facts

- **NCT ID:** NCT05258266
- **Lead sponsor:** Nanjing Zenshine Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-09
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2022-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05258266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05258266, "A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05258266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*